Miyata Hiroshi, Yano Masahiko, Doki Yuichiro, Yasuda Takushi, Yoshioka Setsuko, Sugita Yurika, Takiguchi Shuji, Fujiwara Yoshiyuki, Monden Morito
Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Japan.
J Surg Oncol. 2006 May 1;93(6):477-84. doi: 10.1002/jso.20453.
The aim of this study was to evaluate the usefulness of intra-operative genetic diagnosis of RN node micrometastasis in the decision-making of 3FL for thoracic esophageal cancers.
Eighty-nine patients with middle and lower thoracic esophageal cancer were enrolled in a prospective study, in which 3FL was performed when RN node metastasis was revealed by intra-operative histological examination and/or genetic analysis using real-time RT-PCR assay. For other cases, 2FL was performed.
Of the 89 patients, 3FL was performed for 33 patients and 2FL for 56 patients. In the 3FL group, RN node metastasis was both histologically and genetically positive in 19 patients, histologically negative and genetically positive in 11, and histologically positive and genetically negative in 3, with cervical node metastasis being detected in 7, 3, and 0 patients, respectively. In the 2FL group, only one patient had cervical node recurrence during the follow-up period. The post-operative survival in this study was equivalent to that of the historical controls (3-year survival rates 63.9% vs. 52.3%, P = 0.1513) of 66 3FL patients when 3FL was the first choice for thoracic esophageal cancers.
Intra-operative histological and genetic diagnosis of RN node metastasis may help avoid unnecessary cervical node resection. A Phase III trial should be done.
本研究旨在评估术中对区域淋巴结(RN)微转移进行基因诊断在胸段食管癌三野清扫术(3FL)决策中的实用性。
89例胸段中下段食管癌患者纳入一项前瞻性研究,术中组织学检查和/或采用实时逆转录聚合酶链反应(RT-PCR)检测的基因分析发现RN淋巴结转移时行3FL,其他病例行二野清扫术(2FL)。
89例患者中,33例行3FL,56例行2FL。在3FL组中,19例患者RN淋巴结转移组织学和基因检测均为阳性,11例组织学阴性但基因检测阳性,3例组织学阳性但基因检测阴性,分别有7例、3例和0例患者检测到颈部淋巴结转移。在2FL组中,随访期间仅1例患者出现颈部淋巴结复发。当3FL作为胸段食管癌的首选术式时,本研究患者的术后生存率与66例3FL患者的历史对照(3年生存率63.9%对52.3%,P = 0.1513)相当。
术中对RN淋巴结转移进行组织学和基因诊断可能有助于避免不必要的颈部淋巴结切除。应开展III期试验。